Hycamtin — United Healthcare

Initial criteria

• Diagnosis of small cell lung cancer (SCLC)
• Patient has experienced a relapse of disease after initial first-line chemotherapy (e.g., cisplatin with etoposide)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Hycamtin therapy

Approval duration

12 months